You are viewing the site in preview mode

Skip to main content
Fig. 2 | BMC Neurology

Fig. 2

From: The impact of inotersen on Neuropathy Impairment Score in patients with hereditary transthyretin amyloidosis with polyneuropathy

Fig. 2

Treatment Differences in NIS (a) and NIS-LL (b) Muscle Weakness Domain Change Scores from Baseline to Week 65. Note: Means in purple ink are statistically significantly different from 0 (p < 0.05). Abbreviations: CI, confidence interval; CM, cardiomyopathy; FAP, familial amyloid polyneuropathy; FAS, full analysis set; LS, least-squares; NIS, Neuropathy Impairment Score; NIS-LL, Neuropathy Impairment Score – Lower Limb

Back to article page

BMC Neurology

ISSN: 1471-2377

Contact us